Status:

COMPLETED

To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca

Lead Sponsor:

Rigel Pharmaceuticals

Conditions:

Keratoconjunctivitis Sicca

Eligibility:

All Genders

18-85 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine whether 0.2% and 0.5% R348 Ophthalmic Solutions are safe and effective in the treatment of Patients with Keratoconjunctivitis Sicca.

Eligibility Criteria

Inclusion

  • A history of dry eye (based on the date of initial dry eye symptoms)
  • Use of over-the-counter (OTC) and/or prescription eye drops for dry eye symptoms
  • Corneal fluorescein staining score of at least 2 in the inferior region

Exclusion

  • History of, or a concurrent clinically significant illness, medical condition (other than Keratoconjunctivitis Sicca or Sjögren's syndrome), or laboratory abnormality that, in the Investigator's opinion, could affect the conduct of the study.
  • Use of ophthalmic cyclosporine within 45 days of Visit 1.
  • Use of any topical ophthalmic steroid within 2 weeks of Visit 1.
  • Have worn contact lenses or anticipate using contact lenses during the study.
  • Have a condition or be in a situation that the Investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.
  • Have a history of alcohol or substance abuse that, in the judgment of the Investigator, may impair or risk the subject's full participation in the study.

Key Trial Info

Start Date :

July 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2014

Estimated Enrollment :

204 Patients enrolled

Trial Details

Trial ID

NCT01900249

Start Date

July 1 2013

End Date

July 1 2014

Last Update

October 3 2016

Active Locations (20)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (20 locations)

1

Sall Research Medical Center

Artesia, California, United States, 90701

2

North Bay Eye

Petaluma, California, United States, 94954

3

Martel Medical Eye Group

Rancho Cardova, California, United States, 95670

4

Specialty Eye Care

Parker, Colorado, United States, 808134

To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca | DecenTrialz